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Abstract
Background: Atrial fibrillation (AF) is the most common cardiac arrhythmia. Presenting with a wide range of
symptoms, this disease affects more than 2.66 million people in the United States. Arguably the most
concerning complication faced by patients with AF, is the dramatically increased risk of stroke associated with
this disease. Those with AF are five times more likely to suffer from a stroke than those without. This risk is
partially mitigated by thinning the blood using anticoagulant medications. Warfarin, the most commonly used
anticoagulant, has been available for over 60 years. Warfarin is effective, but dated compared to newer drugs of
its class and associated with inherent difficulties in treatment. Dabigatran, a new anticoagulant that promises
to be easier to administer, may reduce the risk of stroke even further than warfarin. Is dabigatran a better
option than warfarin in reducing stroke in patients with AF?
Method: Exhaustive search of available medical literature was done using CINAHL, Medline-OVID, and
Academic Research Premiere using the following search terms: dabigatran, warfarin, atrial fibrillation, and
stroke. Relevant articles were assessed for quality using the GRADE criteria.
Results: Five studies met inclusion criteria and were included in this systematic review. A large, multicenter,
prospective, open-label, randomized trial with blinded evaluations of outcomes with 18 113 participants
compared two doses of dabigatran with warfarin. It was demonstrated that while both doses of dabigatran
were noninferior, the higher of the two doses was superior to warfarin in reducing stroke and systemic
embolism. Certain risks were increases with dabigatran, such as gastrointestinal bleeding. Subgroup analyses,
also included in the review, demonstrated that dabigatran is superior to warfarin in reducing stroke, even in
subgroups with previous anticoagulant therapy or history of stroke. An observational study with 290
participants revealed that dabigatran is an independent predictor of bleeding and thromboembolic events in
patients undergoing RF ablation therapy for AF.
Conclusion: Dabigatran reduces the risk of stroke to a greater extent than warfarin in patients with AF. It is
also associated with a higher risk of bleeding complications in certain patients. Caution should be taken when
treating with dabigatran, but it is a superior option to warfarin in many patients whose benefits outweigh the
risk.
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Abstract   
Background:  Atrial fibrillation (AF) is the most common cardiac arrhythmia.  
Presenting with a wide range of symptoms, this disease affects more than 2.66 million 
people in the United States.  Arguably the most concerning complication faced by 
patients with AF, is the dramatically increased risk of stroke associated with this disease.  
Those with AF are five times more likely to suffer from a stroke than those without.  This 
risk is partially mitigated by thinning the blood using anticoagulant medications.  
Warfarin, the most commonly used anticoagulant, has been available for over 60 years.  
Warfarin is effective, but dated compared to newer drugs of its class and associated with 
inherent difficulties in treatment.  Dabigatran, a new anticoagulant that promises to be 
easier to administer, may reduce the risk of stroke even further than warfarin.  Is 
dabigatran a better option than warfarin in reducing stroke in patients with AF? 
 
Method:  Exhaustive search of available medical literature was done using CINAHL, 
Medline-OVID, and Academic Research Premiere using the following search terms: 
dabigatran, warfarin, atrial fibrillation, and stroke.  Relevant articles were assessed for 
quality using the GRADE criteria. 
 
Results:  Five studies met inclusion criteria and were included in this systematic review.  
A large, multicenter, prospective, open-label, randomized trial with blinded evaluations 
of outcomes with 18 113 participants compared two doses of dabigatran with warfarin.  It 
was demonstrated that while both doses of dabigatran were noninferior, the higher of the 
two doses was superior to warfarin in reducing stroke and systemic embolism.  Certain 
risks were increases with dabigatran, such as gastrointestinal bleeding.  Subgroup 
analyses, also included in the review, demonstrated that dabigatran is superior to warfarin 
in reducing stroke, even in subgroups with previous anticoagulant therapy or history of 
stroke.  An observational study with 290 participants revealed that dabigatran is an 
independent predictor of bleeding and thromboembolic events in patients undergoing RF 
ablation therapy for AF. 
 
Conclusion:  Dabigatran reduces the risk of stroke to a greater extent than warfarin in 
patients with AF.  It is also associated with a higher risk of bleeding complications in 
certain patients.  Caution should be taken when treating with dabigatran, but it is a 
superior option to warfarin in many patients whose benefits outweigh the risk. 
 
Keywords:  dabigatran, warfarin, atrial fibrillation, stroke 
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Dabigatran Compared to Warfarin in the Reduction of Stroke Risk in Patients With 
Atrial Fibrillation 
BACKGROUND 
 Of the many arrhythmias that can affect the heart, atrial fibrillation (AF) is the 
most common.  It has been estimated to account for one-third of all hospitalizations 
resulting from cardiac rhythm abnormalities. 1 In the United States alone, approximately 
2.66 million people suffer from this disease, a number that is expected to increase to 
more than 5.6 million by the year 2050. 2, 3 As people grow older, their risk for 
developing AF also grows, with a 1.5-fold increase per decade of age. 1, 4 Although some 
patients with AF may not complain of symptoms, it is common for those affected by this 
condition to experience palpitations, a rapid or irregular heartbeat, lightheadedness, 
extreme fatigue, shortness of breath, or chest pain. 
Perhaps more concerning than the above-mentioned symptoms, however, is the 
dramatically increased risk of stroke associated with AF.  The effect of AF on the heart is 
characterized by disorganized electrical activity, which causes an irregular heartbeat.  
This altered heart rhythm causes the flow of blood through the heart to be disrupted, 
increasing the opportunity for thrombi to form.  Research suggests that patients with AF 
are five times more likely to have a stroke than those without. 5 Hart et al reported that 
one out of every six strokes occurs in a patient with AF. 6 Additionally, a study by Marini 
et al concluded that AF is responsible for approximately 25% of all ischemic strokes. 7 
To reduce the high risk of stroke, anticoagulants are administered to prevent 
blood from clotting within the heart.  The most commonly used drug of this type today is 
warfarin, an oral vitamin K antagonist (VKA) introduced more than 60 years ago. 8 
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Warfarin, in preventing stroke, has been studied extensively and has been shown to 
reduce the risk in patients with AF by 64% compared to placebo. 9 Warfarin has made 
dramatic changes in the lives of those with AF, becoming the trusted and preferred 
therapy in the prevention of stroke over the last several decades. 
Although warfarin has been proven a successful treatment in the reduction of 
stroke for patients with AF, it is relatively aged in the realm of oral anticoagulant drugs.  
Even while taking warfarin, patients with AF remain at a much higher risk of stroke than 
those without the disorder.  In addition, VKAs, like warfarin, present with unique 
challenges when administered as part of anticoagulant therapy.  Patients on warfarin need 
frequent monitoring to ensure appropriate therapeutic effect, as there is wide variability 
in dose response and many interactions with foods and drugs.  Poor patient compliance 
and a delayed onset of action are other factors that complicate warfarin therapy. 10 
Dabigatran is a new anticoagulant, which was approved in the United States for 
use in patients with AF in October of 2010. 11 A possibly superior alternative to warfarin, 
dabigatran may even further reduce the risk of stroke in patients with AF. This new drug 
is a direct thrombin inhibitor that promises to require less patient monitoring than that 
which is required by warfarin.  The onset of action is much quicker with dabigatran and 
food or drug interactions are significantly decreases compared to warfarin, making 
administration easier and patient compliance more likely. 12 
If dabigatran is more effective than warfarin in reducing the incidence of stroke in 
patients with AF, many lives could be preserved that may have otherwise been 
significantly impaired or lost.  The question of whether dabigatran is more effective than 
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warfarin in reducing stroke for the population affected by AF is addressed in this 
systematic review. 
METHODS 
 An exhaustive literature search of available research was done using CINAHL, 
Medline-OVID, and Academic Search Premiere using the following search terms: 
dabigatran, warfarin, atrial fibrillation, and stroke.  Studies included in the systematic 
review were restricted to those written in English, as well as being peer-reviewed articles 
conducted on human participants.  Studies were prioritized to include randomized 
controlled trials as well as prospective studies that include data directly comparing the 
efficacy of dabigatran versus warfarin in patients with atrial fibrillation.  Sub-analyses of 
major studies comparing the two drugs were also included.  Inclusionary criteria were 
established to limit articles to those published after 2008.  Relevant articles were assessed 
for quality using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE). 13 
RESULTS 
 The search resulted in 221 articles that contained all of the search fields entered.  
After screening for relevant articles, five were deemed of high relevance and validity, 
also meeting the required inclusionary and exclusionary criteria. 
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RE-LY Trial 
 The randomized evaluation of long-term anticoagulant therapy (RE-LY) trial, 
14supported by a grant from Boehringer Ingelheim, is described by its designers as a 
phase 3, multicenter, prospective, open-label, randomized trial with blinded evaluations 
of all outcomes. 15 The intent of the study was to compare the outcomes of two fixed 
doses of dabigatran to the currently accepted, and widely used, warfarin.  The primary 
outcome measured was stroke or systemic embolism.  The primary safety outcome was 
major hemorrhage, and secondary outcomes were stroke, systemic embolism, and death. 
14
 
In this large study, 18 113 patients with AF were recruited from 951 centers in 44 
countries and randomly assigned to one of three groups, balanced for demographic and 
prognostic equality.  Eligibility for enrollment was limited to patients who had AF 
documented on electrocardiography at a screening, or within 6 months before the time of 
screening, and at least one risk factor for stroke.  Patients were excluded if they had had a 
major stroke within 6 months or any stroke within 14 days before screening, a severe 
heart-valve disorder, a condition that increased risk of hemorrhage, liver disease, or were 
pregnant. 14, 15 
The three randomly assigned treatment groups consisted of dabigatran 110 mg 
(D110) bid, dabigatran 150 mg (D150) bid, or adjusted-dose warfarin.  For those assigned 
to either group receiving dabigatran, the drug was administered, in a blinded fashion, in 
blank capsules containing either 110 mg or 150 mg to be taken two times each day.  
Warfarin was administered in an unblinded fashion in the third group, with the dose 
adjusted in each patient to achieve an international normalized ratio (INR) of 2.0 to 3.0, 
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monitored monthly.  Immediately after randomization, follow-up visits were conducted at 
the following intervals: at 14 days, 1 and 3 months, and every 3 months from then 
forward for the remainder of the first year, and then every 4 months until the study 
concluded. 14 
The enrollment period occurred from December 22, 2005, until December 15, 
2007, in which time all 18 113 patients were entered into the study.  With all three 
treatment groups well balanced, the mean age of the patients was 71 years, with 63.6% 
being men.  The final follow-up visits were conducted between December 15, 2008, and 
March 15, 2009.  The average time of follow-up was 2 years.  Complete follow-up was 
accomplished in 99.9% of patients, with only 20 patients lost to follow-up.  No reason for 
loss was given. 14 
In regards to the primary outcome, stroke or systemic embolism, both doses of 
dabigatran were shown to be noninferior to warfarin, but D150 was also superior.  Stroke 
or systemic embolism occurred in 182 patients receiving D110 (relative risk [RR], 0.91; 
95% confidence interval [CI] 0.74 to 1.11; P=0.34), 134 patients receiving D150 (RR, 
0.66; 95% CI, 0.53 to 0.82; P<0.001), and 199 patients receiving warfarin. 14 
The rates of hemorrhagic stroke were significantly decreased with both doses of 
dabigatran versus warfarin (P<0.001).  Rates in the warfarin group were 0.38% per year 
compared with 0.12% in the D110 group (RR, 0.31; 95% CI, 0.17 to 0.56; P<0.001) and 
0.10% in the D150 (RR, 0.26; 95% CI, 0.14 to 0.49; P<0.001).  For stroke of any type, 
D110 was noninferior, at 1.44% per year (RR, 0.92; 95% CI, 0.74 to 1.13; P=0.41), while 
D150 proved to be significantly superior at 1.01% per year (RR, 0.64; 95% CI, 0.51 to 
0.81; P<0.001), compared to 1.57% per year in the warfarin group. The rates of ischemic 
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or unspecified stroke, compared to warfarin (1.20% per year), were positively and 
negatively affected, depending on the dose of dabigatran administered.  The rate with 
D150 was improved, at 0.92% per year (RR, 0.76; 95% CI, 0.60 to 0.98; P=0.03) but the 
rate increased to 1.34% per year when D110 was administered (RR, 1.11; 95% CI, 0.89 
to 1.40; P=0.35). 14 
Rates of death from any cause were 4.13% per year in the warfarin group, 
compared with 3.75% per year in the D110 group (RR, 0.91; 95% CI, 0.80 to 1.03; 
P=0.13) and 3.64% per year in the D150 group (RR, 0.88; 95% CI, 0.77 to 1.00; 
P=0.051).  These results were not statistically significant, however.  The rate of major 
bleeding was 3.36% per year in the warfarin group, compared with 2.71% in the D110 
group (RR, 0.80; 95% CI, 0.69 to 0.93; P=0.003) and 3.11% per year in the D150 group 
(RR, 0.93; 95% CI, 0.81 to 1.07; P=0.31).  Although the rate of all types of major 
bleeding combined was reduced with dabigatran, the rate of major gastrointestinal 
bleeding was significantly increased in the D150 group (RR, 1.50; 95% CI, 1.19 to 1.89; 
P<0.001). 14 
Rates of myocardial infarction (MI) increased in the dabigatran groups, as 
compared with the warfarin group.  For warfarin, the rate of MI was 0.53% per year, 
while rates were 0.72% per year with D110 (RR, 1.35; 95% CI, 0.98 to 1.87; P=0.07) and 
0.74% per year with D150 (RR, 1.38; 95% CI, 1.00 to 1.91; P=0.048). 14 
The net clinical benefit outcome for the study consisted of major vascular events, 
major bleeding, and death.  Combined, the rates for this outcome were 7.64% per year 
with warfarin, compared with 7.09% per year with D110 (RR, 0.92; 95% CI, 0.84 to 
1.02; P=0.10) and 6.91% per year with D150 (RR, 0.91; 95% CI, 0.82 to 1.00; P=0.04). 14 
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According to the researchers of this study, the only adverse effect that was 
significantly more common with dabigatran, compared to warfarin, was dyspepsia.  This 
occurred in 5.8% (348) of patients on warfarin, 11.8% (707) of patients receiving D110, 
and 11.3% (688) of patients receiving D150.  The P value for both dabigatran groups 
versus warfarin was P<0.001. 14 
Subgroup Analyses of the RE-LY Trial 
 Since the publication of the RE-LY trial in 2009, various researchers and teams 
have analyzed subgroups within the participants of the study, using the original data 
acquired by Connolly et al to undergo unique exploratory studies.  These studies have 
served to validate the results of the RE-LY trial or to suggest new findings based on the 
data collected therein.  The following are subgroup analyses of the RE-LY trial data. 
 VKA-naïve vs. VKA-experienced patients—This study, 16 published in 2010 by 
Ezekowitz et al, aimed to determine whether the benefits of either dose of dabigatran 
were affected by previous VKA exposure.  All participants in the RE-LY trial fit into one 
of two subgroups in terms of VKA exposure: VKA-naïve (≤62 days of lifetime VKA 
exposure, with 33% never prescribed a VKA) and VKA-experienced patients with AF.  
Warfarin, D110, and D150 were compared in balanced populations of these two 
subgroups. 14-16 
 Stroke or systemic embolism rates in the D110 group were similar in both VKA-
naïve and VKA-experienced groups compared with warfarin (RR, 0.93; 95% CI, 0.70 to 
1.25; P=0.65 and RR, 0.87; 95% CI, 0.66 to 1.15; P=0.32, respectively).  Interaction was 
not significant between the subgroups, at P=0.72.  The rates for the D150 group were 
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significantly lower in both VKA-naïve and VKA-experienced groups compared with 
warfarin (RR, 0.63; 95% CI, 0.46 to 0.87; P=0.005 and RR, 0.66; 95% CI, 0.49 to 0.89; 
P=0.007, respectively).  Interaction was not significant between the subgroups with D150 
either, at P=0.84.  With the primary outcome, among others, the results of the study 
concluded that previous VKA exposure does not influence the benefits of dabigatran at 
either dose compared with warfarin. 16 
 Previous TIA or stroke—In this study 17 conducted by Diener et al, the effects of 
dabigatran compared with warfarin are assessed in the subgroup of patients with previous 
transient ischemic attack (TIA) or stroke.  Of the patients enrolled in the RE-LY trial, 
3623 had a previous TIA or stroke.  The rate of stroke or systemic embolism among those 
patients was higher than in those without (171 of 3 623 [2.38% per year] versus 348 of 14 
489 [1.22% per year]; p<0.0001).  Within the subgroup of patients who had previous TIA 
or stroke, there were 1195 patients were from the D110 group, 1233 from the D150 
group, and 1195 from the warfarin group. 17 
 For the outcome of stroke or systemic embolism, the interaction between the 
subgroup with prior TIA or stroke, and those without, was non-significant for both the 
D110 and D150 groups (P for interaction=0.62 and P for interaction=0.34, respectively). 
The interaction was insignificant regarding stroke, by itself, in both the D110 and D150 
groups as well (P for interaction=0.85 and P for interaction=0.28, respectively).  There 
was no significant interaction found in any other outcome of the trial.  The study 
concludes that the effects of D110 and D150 in patients with previous TIA or stroke are 
consistent with those in the other patients in RE-LY.  The effect of dabigatran is not 
influenced by prior TIA or stroke. 17 
 14
 Stroke after cardioversion—This study, 18 by Nagarakanti et al, focused on the 
risk of stroke, post-cardioversion, in patients treated with dabigatran compared to 
warfarin, prior to cardioversion.  A total of 1983 cardioversions were performed in 1270 
patients during the course of the RE-LY trial: 647 in the D110 group, 672 in the D150 
group, and 664 in the warfarin group.  The majority of the cardioversions were electric: 
85.6%, 81.9%, and 83.3% in D110, D150, and warfarin, respectively.  The remainder 
were pharmacological, except for 2 in the D110 group, which were spontaneous. 18 
 Stroke or systemic embolism rates within 30 days of cardioversion were low 
among all three groups: 0.77% with D110, 0.30% with D150, and 0.60% with warfarin.  
Neither doses of dabigatran were significantly different than warfarin, with D110, 
P=0.71, and D150, P=0.45.  Rates of major bleeding in all three groups were also low: 
1.7% in D110, 0.6% in D150, and 0.6% in warfarin. 18 
 The major conclusion of the study was that rates of major bleeding and stroke 
within 30 days of cardioversion, in patients on either dose of dabigatran, are low and 
comparable to rates with warfarin. 18 
Dabigatran vs. Warfarin in Patients Undergoing Radiofrequency Ablation for AF 
 This multicenter, observational study, 19 published in March 2012, was designed 
to assess the risks of dabigatran, compared with warfarin, when used in patients with AF 
prior to undergoing radiofrequency (RF) ablation.  Patients included in the study 
consisted of those who underwent RF ablation for drug-refractory, symptomatic AF at 
one of eight high-volume electrophysiology laboratories between January 2010 and July 
2011.  The mean age of the study population was 60 years, with 79% being male, and 
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57% having paroxysmal AF.  The study was approved by a local institutional review 
board. 19 
 The patient population was comprised of 290 patients with 145 patients in each of 
two groups, a dabigatran group and a warfarin group. The dabigatran group was made up 
of patients receiving D150 for at least 30 days prior to ablation.  In the warfarin group, 
patients were receiving anticoagulation with warfarin for at least 30 days prior to 
ablation.  The patients of each group were matched by age, sex, type of AF, and 
institution.  Patients were excluded from the study if the INR was not between 2.0 and 
3.5 at the time of the ablation procedure, or if the ablation was performed with the help of 
a remote navigation system.  The ablation procedures were normalized by following 
standardized protocols. 19 
 The primary safety outcome was a composite of bleeding and thromboembolic 
complications.  Bleeding complications included hematomas, pericardial effusions, any 
bleeding requiring blood transfusions, and tamponade.  Thromboembolic complications 
included stroke and TIAs after ruling out intracranial hemorrhage.  All events occurring 
within 30 days of the RF ablation were included in the analysis. 19 
 Of the 290 total patients, 32 (11%) had either bleeding or embolic complications.  
Of those, 29 (10%) had bleeding complications and 3 (1%) had thromboembolic 
complications.  In the dabigatran group, 6% of patients had major bleeding complications 
(cardiac tamponade requiring drainage), as compared with 1% in the warfarin group 
(P=0.019).  Total bleeding rate for the dabigatran group was 14%, as compared with 6% 
in the warfarin group (P=0.031).  The rate of composite bleeding and embolic 
complications in the dabigatran group was 16%, as compared with 6% in the warfarin 
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group (P=0.009).  The difference in all three of these complications between dabigatran 
and warfarin was statistically significant.  The rate of embolic complications alone was 
non-significantly increased in the dabigatran group (2%), as compared with 0% in the 
warfarin group (P=0.25). 19 
 In univariable analysis of predictors of complication, the only predictors of 
bleeding were the use of dabigatran (p=0.031) and age older than 75 years (P=0.004).  
The only univariable predictors of the composite of bleeding and thromboembolic 
complications was also dabigatran (P=0.009) and age older than 75 (P=0.008).  In 
multivariable logistic regression analysis including age older than 75, sex, AF type, and 
the use of dabigatran, the only independent predictors of bleeding or thromboembolic 
complications were dabigatran use (odds ratio, 2.76; 95% CI, 1.22 to 6.25; P=0.01) and 
age older than 75 (odds ratio, 3.82; 95% CI, 1.09 to 13.35; P=0.04).  Dabigatran use was 
found to be an independent predictor of both bleeding complications (odds ratio, 2.34; 
95% CI, 1.02 to 5.39; P=0.046) and composite of bleeding and thromboembolic events. 19      
DISCUSSION 
 Although dabigatran is relatively new in the world of anticoagulant therapy, it 
appears to have compelling applications as an alternative to warfarin in the treatment of 
patients with AF. 
Stroke or Systemic Embolism, and Stroke Alone 
Strong evidence produced in recent years points to the fact that dabigatran has 
significant benefits, above that of warfarin, in reducing the risk of stroke for patients with 
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AF. 14, 16-18 The RE-LY trial 14, presumably the largest study conducted to date on the 
comparison of dabigatran and warfarin, demonstrated that, although warfarin is beneficial 
for AF patients, dabigatran is even better.  The rate for patients in this cohort to 
experience a stroke or systemic embolism of any kind was 1.69% per year for those 
receiving warfarin.  When that is compared to 1.11% per year for those receiving D150, it 
becomes easy to understand that this new drug has potential to improve the lives of those 
who suffer from this condition.  Based on those rates, for every 1000 patients on 
anticoagulant warfarin therapy, 6 lives could potentially be preserved by switching to a 
therapy of D150.  When stroke was considered by itself, D150 significantly reduced the 
rate per year, at 1.01%, compared with warfarin, at 1.57%.  Based on the RE-LY trial 14 
data, D150 therapy is far superior to adjusted-dose warfarin to reduce the dramatic risk of 
stroke associated with AF.  
This benefit of D150 over warfarin was further analyzed in subgroup analyses 16-18 
of the RE-LY trial 14.  Ezekowitz et al 16 showed that whether or not patients have had 
prior exposure to VKA therapy is immaterial, reporting that the beneficial effects of 
dabigatran in reducing the risk of stroke or systemic embolism are superior to warfarin. 
Diener et al 17 found that past history of TIA or stroke did not negatively affect the 
comparative benefit of D150 over warfarin. With the understanding that cardioversion 
treatment for patients in AF is a known risk factor for stroke or systemic embolism, 20 
Nagarakanti et al 18 aimed to determine whether or not dabigatran use before the 
procedure increased risk.  It was determined that rates of stroke or systemic embolism 
within 30 days of cardioversion were low and noninferior in any dose of dabigatran 
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compared to warfarin.  Dabigatran is, therefore, a reasonable alternative to warfarin in 
patients undergoing cardioversion.  
Not all research has shown dabigatran to be a safe alternative to warfarin 
however, as some applications of the drug in AF therapy may actually increase the risk of 
harm to patients.  The study by Lakkireddy et al 19, published in March 2012, found a 
discrepancy in the perceived benefit of dabigatran over warfarin that wasn’t reported in 
the RE-LY trial 14.  This observational study found that D150 therapy before a patient 
undergoes RF ablation actually increases the risk of both thromboembolic (stroke or TIA) 
and bleeding complications within 30 days of the procedure.  The multivariate regression 
analysis done to assess predictors of complications found D150 before RF ablation to be 
an independent predictor of bleeding or thromboembolic complications.  This data, 
although new, and contrary to what was previously understood about the drug, lends 
great insight into the reality of dabigatran therapy.  With RF ablation therapy becoming a 
more widely used intervention for AF that cannot be controlled with pharmacotherapy, 
caution should be given when considering dabigatran. 21 
Other Outcomes 
 One of the most negative effects of warfarin therapy is the increased risk of 
bleeding, such as intracranial hemorrhage.  Warfarin doubles the risk of intracranial 
hemorrhage compared to aspirin. 9 The RE-LY trial 14 found that the rate of this 
complication with either dose of dabigatran (D110 or D150) was less than a third of the 
rate with warfarin. This evidence further strengthens the case for dabigatran as an 
alternative to warfarin.  For rates of all major bleeding complications, the D110 dose 
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resulted in a significant decrease, while the D150 rates were decreased, but not to a 
statistically significant degree, making both doses at least noninferior to warfarin, 
according to the RE-LY trial 14.  This information is put into perspective by the results 
from Lakkireddy et al 19, which show a significant risk of bleeding complications with 
dabigatran over warfarin in patients undergoing RF ablation.  
Due to the nature and results of the primary outcomes measured in the RE-LY 
trial 14, it is not surprising that rates of death were lower in both groups receiving 
dabigatran.  The most significant decrease in mortality was the rate of death from 
vascular causes in the D150 group, which was approximately 15% less than that in the 
warfarin group. 
Limitations of Studies 
 Research to assess the effectiveness of dabigatran versus that of warfarin has 
inherent limitations that must be considered.  Due to warfarin’s mechanism of action, 
therapy must be closely monitored in all patients receiving the drug.  In the RE-LY trial 
14
, this requirement prevented the patients in the warfarin group, and the study 
administrators, from being blinded as to which treatment they received.  The open-label 
use of warfarin increased the risk of bias in reporting.  A blinded evaluation of outcome 
events was implemented in the study design in effort to reduce that risk.  Risk of bias in 
the RE-LY trial 14 was also a consideration due to it being funded by Boehringer 
Ingelheim, the manufacturer of dabigatran.  
 Regarding the subgroup analyses reviewed 16-18, it is important to understand that, 
although they tend to support the results of the RE-LY trial 14 and offer new insights into 
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the use of dabigatran, these studies should be labeled as exploratory in nature, as the 
outcomes analyzed were not predetermined in the RE-LY trial. 
 In the study done by Lakkireddy et al 19 regarding complications after RF 
ablation, a limitation to note was the sample size of 290 patients.  Although it provides 
invaluable data concerning the safety of dabigatran, this number represents only a small 
fraction of the sample size in the RE-LY trial 14, and therefore more research with greater 
participation is warranted.  This study was also observational, which is a limitation 
compared to a study that has been randomized and concealed.  It is also possible that 
confounding variables, such as operator-specific techniques in the ablation procedures, 
were unaccounted for and affected the results.  
Clinical Application 
 Given its limitations, the RE-LY trial 14 was a large and well-designed study that 
revealed important information about dabigatran and its potential as a promising 
anticoagulant agent with the ability to save lives.  The validity of the study was 
reinforced by the use of a dose gradient, not only comparing dabigatran with warfarin, 
but also comparing the effect of D110 with D150.  It was clearly demonstrated that D150 
has a superior ability to prevent stroke and systemic embolism than warfarin, while D110 
proved to be noninferior.  With the understanding that all anticoagulant therapy 
inherently raises the risk of bleeding, this comparison of D110 with D150 lends reason to 
believe that the dose could be adjusted to achieve a safe and desired effect in each unique 
patient, especially for those at higher risk of bleeding. 
 The subgroup analyses reviewed in this study serve to both support the evidence 
produced by the RE-LY trial 14 and also provide clinicians with greater understanding of 
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the appropriateness as to when the drug should be administered.  Though their data 
mainly serve to show the consistency of various subgroup results with the overall results 
of the original trial, this information can illuminate confusion when considering placing a 
subgroup patient on dabigatran.  Knowing that dabigatran has the same effect on patients 
with differing medical histories increases its therapeutic value and will improve provider 
confidence in prescribing. 
 Dabigatran is not a flawless alternative to warfarin, however.  Connolly et al 14 of 
the RE-LY trial discovered that occurrence of dyspepsia is significantly increased in both 
doses of the drug compared to warfarin.  Although this may not appear to be a major 
obstacle for some, it is reasonable to believe that this side effect could inhibit patient 
compliance if not tolerated or treated properly.  Interestingly, the RE-LY trial 14 also 
produced evidence that, even though rates of major bleeding were decreased as a whole, 
the rate of major gastrointestinal bleeding was significantly increased in the D150 group.  
This is a serious problem that warrants further investigation, as to ensure the safety of 
patients who might otherwise receive more harm than benefit from therapy.  In a separate 
subgroup analysis of the RE-LY trial 14, focused solely on the risk of bleeding with 
dabigatran versus warfarin, it was determined that the D150 dose was associated with a 
significant increase in the rate of extracranial bleeding in patients 75 years and older. 22 
 On December 7, 2011, just over a year from the time dabigatran was approved in 
the United States for prevention of stroke in AF patients, the Food and Drug 
Administration (FDA) issued a safety warning 23 in response to research that revealed 
warning signs of bleeding risk with dabigatran use.  The FDA stated that they are 
evaluating reports of serious bleeding events in patients taking dabigatran, but that, at this 
 22
time, they believe that the drug provides an important health benefit when used as 
directed.  This logic is supported by the net clinical benefit measured in the RE-LY trial 
14
, which is a measurement of the overall benefit and risk of dabigatran.  Given the risks 
associated with this drug, Connolly et al reported that the net clinical benefit, while 
similar to warfarin in the D110 group, was significantly increased in the D150 group.  
CONCLUSION 
 Dabigatran decreases the risk of stroke and systemic embolism in patients with 
AF to a greater extent than warfarin.  It also carries with it a significant risk of bleeding, 
which in some cases is greater than the same risk with warfarin therapy.  Though more 
research will surely provide greater insight into the application of dabigatran and its role 
in anticoagulant therapy, it is clear that, in many patients, this drug has the ability save 
lives at an increased rate than the current standard of care. 
 Great care and consideration should be taken when administering dabigatran, but 
when the benefits appear to outweigh the given risks, it is not only an appropriate 
alternative to warfarin, but a superior option to preserve the lives of those who suffer 
from this common arrhythmia. 
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Table I. Characteristics of Reviewed Articles and Summary of Findings 
 
*The RE-LY trial was not fully blinded, and therefore not upgraded because of observed dose-response gradient. 
Quality Assessment Summary of Findings 
Importance  Downgrade Criteria Upgrade Criteria  Number of Patients Effect 
Quality 
No. of 
Studies 
Design Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Large effective 
Magnitude 
Confounding 
Factors 
reducing effect 
Dose-
response 
gradient 
Study 
110 mg Dab 
(1) 
150 mg Dab 
(2) 
Warfarin 
(control) 
RR 
(1) 
P Value 
(1) 
RR 
(2) 
P Value 
(2) 
Stroke or Systemic Embolism 
1 1 Prospective 
Serious 
limitations* 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias likely - - Yes* RE-LY
 14
 182/6015 134/6076 199/6022 0.91 0.34 0.66 <0.001 Moderate Critical 
Stroke 
2 
1 Prospective 
1 Observational 
Serious 
limitations* 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias likely - - Yes* 
RE-LY
 14
 171/6015 122/6076 185/6022 0.92 0.41 0.64 <0.001 
Moderate Critical 
Lakkireddy et al
 19
 - 3/145 0/145 - - >1 0.009 
Major Bleeding 
2 
1 Prospective 
1 Observational 
Serious 
limitations* 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias likely - - Yes* 
RE-LY
 14
 322/6015 375/6076 397/6022 0.80 0.003 0.93 0.31 
Moderate Critical 
Lakkireddy et al
 19
 - 9/145 1/145 - - 9 0.019 
Death 
1 1 Prospective 
Serious 
limitations* 
No serious 
indirectness 
No serious 
imprecision 
No serious 
inconsistencies 
No bias likely - - Yes* RE-LY
 14
 446/6015 438/6076 487/6022 0.91 0.13 0.88 0.051 Moderate Critical 
